Ultragenyx Announces Positive 36-Week Data from Phase 3 Study of DTX301 AAV8 Gene Therapy for the Treatment of Ornithine Transcarbamylase (OTC) Deficiency
Go back to Ultragenyx Announces Positive 36-Week Data from Phase 3 Study of DTX301 AAV8 Gene Therapy for the Treatment of Ornithine Transcarbamylase (OTC) Deficiency| ULTRAGENYX PHARM (NASDAQ: RARE) | Delayed: 32.38 -1.01 (3.02%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $33.39 | 52 Week High | $117.12 | |||
| Open | $33.13 | 52 Week Low | $46.52 | |||
| Day High | $33.49 | P/E | N/A | |||
| Day Low | $32.34 | EPS | $-1.97 | |||
| Volume | 2,635,815 | |||||
